Literature DB >> 6397139

The digestive tract in immunocompromised patients: importance of maintaining its resistance to colonization, especially in hospital in-patients and those taking antibiotics.

D van der Waaij.   

Abstract

The colonization resistance (CR) of the gastrointestinal tract to potential pathogens depends partly on factors within the host but to a greater extent on the normal (anaerobic) gut flora. Its strength varies between individuals. These individual differences in resistance to colonization by pathogenic microorganisms may explain differences in susceptibility to infection. CR is lowered by remission-inducing treatment (radiation and/or chemotherapy) in leukaemia, but more severely by certain antibiotics. Development (by selection or transfer) of resistance to these antibiotics may lead to overgrowth and penetration of the mucosal lining by the overgrowing (potentially) pathogenic bacteria. Other antibiotics however, if sufficiently dosed, have been found to eliminate (potential) pathogens selectively without decreasing CR. This selective decontamination of the gastrointestinal tract has been successfully used prophylactically in neutropenic patients but needs to be monitored bacteriologically. It should perhaps be used more widely in the hospital to control development and spread of antibiotic-resistant strains.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6397139     DOI: 10.1007/BF02386238

Source DB:  PubMed          Journal:  Antonie Van Leeuwenhoek        ISSN: 0003-6072            Impact factor:   2.271


  63 in total

1.  Co-trimoxazole versus non-absorbable antibiotics in acute leukaemia.

Authors:  J G Watson; B Jameson; R L Powles; T J McElwain; D N Lawson; I Judson; G R Morgenstern; H Lumley; H E Kay
Journal:  Lancet       Date:  1982-01-02       Impact factor: 79.321

2.  Plasmid-controlled colonization factor associated with virulence in Esherichia coli enterotoxigenic for humans.

Authors:  D G Evans; R P Silver; D J Evans; D G Chase; S L Gorbach
Journal:  Infect Immun       Date:  1975-09       Impact factor: 3.441

3.  Colonization resistance of the digestive tract and the spread of bacteria to the lymphatic organs in mice.

Authors:  D van der Waaij; J M Berghuis-de Vries
Journal:  J Hyg (Lond)       Date:  1972-06

4.  The effect of three frequently applied antibiotics on the colonization resistance of the digestive tract of mice.

Authors:  H A Thijm; D van der Waaij
Journal:  J Hyg (Lond)       Date:  1979-06

5.  Human oral defenses against gram-negative rods.

Authors:  F M Laforce; J Hopkins; R Trow; W L Wang
Journal:  Am Rev Respir Dis       Date:  1976-11

6.  Prevention of infection by trimethoprim-sulfamethoxazole plus amphotericin B in patients with acute nonlymphocytic leukaemia.

Authors:  A W Dekker; M Rozenberg-Arska; J J Sixma; J Verhoef
Journal:  Ann Intern Med       Date:  1981-11       Impact factor: 25.391

7.  Inhibition of Escherichia coli translocation from the gastrointestinal tract by normal cecal flora in gnotobiotic or antibiotic-decontaminated mice.

Authors:  R D Berg
Journal:  Infect Immun       Date:  1980-09       Impact factor: 3.441

8.  The screening of four aminoglycosides in the selective decontamination of the digestive tract in mice.

Authors:  D van der Waaij; J Aberson; H A Thijm; G W Welling
Journal:  Infection       Date:  1982-01       Impact factor: 3.553

9.  Bacteriological aspects of selective decontamination of the digestive tract as a method of infection prevention in granulocytopenic patients.

Authors:  H G de Vries-Hospers; D T Sleijfer; N H Mulder; D van der Waaij; H O Neiweg; H K van Saene
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

10.  Infection by the distribution of biotypes of enterobacteriacease species in leukaemic patients treated under ward conditions and in units for protective isolation in seven hospitals in Europe.

Authors:  D Van der Waaij; T M Tielemans-Speltie; A M De Roeck-Houben
Journal:  Infection       Date:  1977       Impact factor: 3.553

View more
  7 in total

Review 1.  Evidence of immunoregulation of the composition of intestinal microflora and its practical consequences.

Authors:  D van der Waaij
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

2.  Colonization pattern of the digestive tract by potentially pathogenic microorganisms: colonization-controlling mechanisms and consequences for antibiotic treatment.

Authors:  D van der Waaij
Journal:  Infection       Date:  1983       Impact factor: 3.553

3.  Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model.

Authors:  Margot Fijlstra; Mithila Ferdous; Anne M Koning; Edmond H H M Rings; Hermie J M Harmsen; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2014-11-08       Impact factor: 3.603

4.  Double beta-lactam regimen compared to an aminoglycoside/beta-lactam regimen as empiric antibiotic therapy for febrile granulocytopenic cancer patients.

Authors:  J H Joshi; K A Newman; B W Brown; R S Finley; R L Ruxer; M A Moody; S C Schimpff
Journal:  Support Care Cancer       Date:  1993-07       Impact factor: 3.603

5.  Effects of selective decontamination on gram-negative colonisation, infections and development of bacterial resistance in esophageal resection.

Authors:  G W Tetteroo; J H Wagenvoort; C Ince; H A Bruining
Journal:  Intensive Care Med       Date:  1990       Impact factor: 17.440

6.  Vibrio vulnificus induces the death of a major bacterial species in the mouse gut via cyclo-Phe-Pro.

Authors:  Jeong-A Kim; Bo-Ram Jang; Yu-Ra Kim; You-Chul Jung; Kun-Soo Kim; Kyu-Ho Lee
Journal:  Microbiome       Date:  2021-07-20       Impact factor: 14.650

7.  Site and strain-specific variation in gut microbiota profiles and metabolism in experimental mice.

Authors:  Melissa K Friswell; Helen Gika; Ian J Stratford; Georgios Theodoridis; Brian Telfer; Ian D Wilson; Andrew J McBain
Journal:  PLoS One       Date:  2010-01-05       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.